Vickram Tejwani, MD
Pulmonary Disease · Cleveland, OHNPI 1578907978
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $42,577 of the $58,090 with a category attached, or 73.3%. 8 manufacturers reported payments, led by Sanofi at 57.7% of the total. 2025 is the largest year on record at $39,942, more than ten times the $2,254 reported in 2020. Among pulmonary disease clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 50 payments — averaging $1161.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$34K
- Regeneron Healthcare Solutions, Inc.$17K
- Phadia US Inc.$3K
- CSL Behring$2K
- AstraZeneca$2K
- Cipla USA Inc.$1K
- plus $260 from 2 others
Across 23 payments — averaging $5069.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Grifols Therapeutics LLC$92K
- Grifols Biologicals LLC$25K
What the payments were for
- Consulting fees$9,85317%
- Speaking & faculty fees$42,57773%
- Travel & lodging$4,2857%
- Food & beverage$1,3752%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 23 | $33,532 |
| Regeneron Healthcare Solutions, Inc. | 17 | $16,669 |
| Phadia US Inc. | 2 | $2,500 |
| CSL Behring | 1 | $2,254 |
| AstraZeneca | 3 | $1,875 |
| Cipla USA Inc. | 1 | $1,000 |
| Verona Pharma, Inc. | 2 | $248 |
| Inogen, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$58,090 in reported general payments places this provider in the 90th percentile of 571 pulmonary disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 53 | $200,947 |
| XolairOmalizumab | 19 | $66,771 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 24 | $65,109 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $55,681 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 38 | $41,804 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 36 | $40,429 |
| DuleraMometasone/Formoterol | 51 | $29,464 |
| Spiriva HandihalerTiotropium Bromide | 20 | $18,495 |
| Incruse ElliptaUmeclidinium Bromide | 32 | $18,140 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $12,060 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $7,984 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 30 | $6,667 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 115 | $4,069 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $3,762 |
| Azelastine Hcl | 54 | $1,820 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBreztri Aerosphere, Symbicort | $1,875 | $49,78856 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 571 pulmonary disease providers in Ohio.
Other pulmonary disease in Cleveland
- Kristin HighlandCleveland$551K
- Joseph CiceniaCleveland$350K
- Michael MachuzakCleveland$286K
- Marie BudevCleveland$159K
- Leslie TolleCleveland$136K
- Elliott DasenbrookCleveland$114K
- James StollerCleveland$101K
- Gustavo Heresi DavilaCleveland$98K
- Bryan BennCleveland$96K
- Thomas GildeaCleveland$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.